|
ISRCTN
|
ISRCTN02628492
|
|
ClinicalTrials.gov identifier
|
|
|
Public title
|
Prevention of post-cataract surgery macula oedema with prophylactic ketorolac
|
|
Scientific title
|
Prevention of pseudophakic cystoid macula oedema with pre- and post-operative ketorolac
|
|
Acronym
|
N/A
|
|
Serial number at source
|
1.2
|
|
Study hypothesis
|
To assess whether patients treated with ketorolac 3 days pre- and 3 weeks post-operatively in combination with post-operative steroid drops have a lower incidence of cystoid macula oedema (CMO) following cataract surgery than those receiving standard clinical care (pre-operative topical flurbiprofen 1 hour prior to surgery and post-operative steroid drops).
|
|
Ethics approval
|
Ethics approval pending as of 07/07/2008. London-Surrey Borders ethics committee will be meeting on 9th July 2008.
|
|
Study design
|
Single-blind randomised controlled trial
|
|
Countries of recruitment
|
United Kingdom
|
|
Disease/condition/study domain
|
Cystoid macular oedema (CMO)
|
|
Participants - inclusion criteria
|
1. Patients undergoing routine cataract surgery without an additional procedure
2. Patients with risk factors for developing CMO, such as pre-existing diabetes
3. Aged 18 to 75 years, male and female
Patients with epiretinal membranes or age-related macular degeneration (ARMD) will be analysed separately.
|
|
Participants - exclusion criteria
|
1. Patients who have previously had a reaction to ketorolac
2. Patients who are on systemic non-steroidal anti-inflammatories or steroids
|
|
Anticipated start date
|
12/07/2008
|
|
Anticipated end date
|
12/10/2009
|
|
Status of trial
|
Completed |
|
Patient information material
|
Not available in web format, please use the contact details below to request a patient information sheet
|
|
Target number of participants
|
1400
|
|
Interventions
|
1. Intervention: ketorolac eye drops (0.4%) - 1 eye drop 4 times a day for 3 days before the operation and 3 weeks after the operation
2. Control arm: usual clinical care - 1 drop of flurbiprofen eye drop 1 hour before surgery and Maxidex® eye drop three times a day for 3 weeks post-cataract surgery
|
|
Primary outcome measure(s)
|
Central macula thickness as measured on optical coherence tomography.
The primary and secondary outcomes will be measured at baseline (prior to surgery), 1 month after surgery, 2 months after surgery and 3 months after surgery.
|
|
Secondary outcome measure(s)
|
1. Logarithmic minimal angle of resolution (LogMAR) visual acuity
2. Contrast sensitivity
3. Adverse events
The primary and secondary outcomes will be measured at baseline (prior to surgery), 1 month after surgery, 2 months after surgery and 3 months after surgery.
|
|
Sources of funding
|
Frimley Park Hospital NHS Foundation Trust (UK) - Ophthalmology Research Funding will cover any extra costs incurred
|
|
Trial website
|
|
|
Publications
|
|
|
Contact name
|
Mrs
Geeta
Menon
|
|
Address
|
Frimley Park Hospital NHS Foundation Trust
Portsmouth Road
|
|
City/town
|
Frimley
|
|
Zip/Postcode
|
GU16 7UJ
|
|
Country
|
United Kingdom
|
|
Sponsor
|
Frimley Park Hospital NHS Foundation Trust (UK)
|
|
Address
|
Portsmouth Road
|
|
City/town
|
Frimley
|
|
Zip/Postcode
|
GU16 7UJ
|
|
Country
|
United Kingdom
|
|
Sponsor website:
|
http://www.frimleypark.nhs.uk/
|
|
Date applied
|
06/07/2008
|
|
Last edited
|
22/07/2008
|
|
Date ISRCTN assigned
|
22/07/2008
|
